| 30 days | 90 days | 120 days | |
|---|---|---|---|
| Average return | -3% | 8.2% | 15.1% |
| Success rate | 40% | 68% | 82% |
| Transactions |
13
0% Buy
|
34
71% Buy
|
47
69% Buy
|
| Position | Company | Period |
|---|---|---|
| Independent Director | Editas Medicine Inc | July 28, 2016 - |
| President - Research and Development | Alnylam Pharmaceuticals Inc | March 1, 2018 - |
| Independent Director | Scholar Rock Holding Corporation | May 21, 2019 - May 29, 2020 |
| Executive Vice President - Research and Development | Alnylam Pharmaceuticals Inc | Jan. 3, 2017 - March 1, 2018 |
| Executive Vice President - Research and Development ,Chief Medical Officer | Alnylam Pharmaceuticals Inc | Dec. 1, 2014 - Jan. 3, 2017 |
| Executive Vice President, Chief Medical Officer | Alnylam Pharmaceuticals Inc | June 21, 2012 - Dec. 1, 2014 |
| Senior Vice President, Chief Medical Officer | Alnylam Pharmaceuticals Inc | June 9, 2011 - June 21, 2012 |
Plus unlocks the full transaction history.
Billed monthly · Cancel anytime